Daily FNArena News

FNArena is one of few remaining truly independent providers of financial markets analysis, financial commentary and business news in Australia. Our Daily Financial News is not based on ASX lodgements or corporate press releases, but more so on updated views, insights and responses from stockbrokers and other experts. FNArena is not aligned with any financial institution, hence the moniker “independent”. We have a long history of publishing out-of-consensus views and market analysis. Our quest is not to be bullish or bearish, but to correctly assess future trends.

Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | SMSFundamentals | Technicals | Treasure Chest |

Previous Stories

Market Share Gains Key to ResMed’s Outlook

Aug 15 2022 - Australia

Following FY22 results, brokers set higher price targets for ResMed on average and expect market share gains

FNArena Corporate Results Monitor – 15-08-2022

Aug 15 2022 - Australia

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

FNArena Corporate Results Monitor – 12-08-2022

Aug 12 2022 - Australia

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps

FY22 results for Australian Clinical Labs missed expectations and brokers await an uptick in non-covid testing

FNArena Corporate Results Monitor – 11-08-2022

Aug 11 2022 - Australia

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Block Still Paying For Afterpay Acquisition

Aug 11 2022 - Australia

Block’s buy now pay later segment continues to drag on portfolio performance, but brokers largely continue to back the integration opportunity for Afterpay and Cash App

FNArena Corporate Results Monitor – 10-08-2022

Aug 10 2022 - Australia

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Megaport: Focus Returns To Global Potential

Aug 10 2022 - Small Caps

Megaport’s FY22 result highlighted significant metrics disclosed for the first time, underpinning broker views of a solid longer term growth story

Trouble On The Aurizon

Aug 10 2022 - Australia

An in-line result from Aurizon Holdings was somewhat overshadowed by guidance for FY23 that has largely disappointed the brokers

FNArena Corporate Results Monitor – 09-08-2022

Aug 09 2022 - Australia

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

« Older Stories
Newer Stories »

Analyse The Market From A Different Angle

ICARUS SIGNAL

Consensus price targets can be a useful tool to assess whether stocks are running too hard, or falling too deeply.
R-FACTOR

Relative ranking of ASX200 stocks in accordance with consensus forecasts for growth, valuation and yield.
SENTIMENT INDICATOR

Evaluate circa 400 ASX-listed stocks on the basis of High/Low expert sentiment, forecast dividend yield.

Latest News

1
The Market In Numbers – 2 May 2026

9:09 AM - Australia
2
ASX Winners And Losers Of Today – 01-05-26

May 01 2026 - Daily Market Reports
3
FNArena Corporate Results Monitor – 01-05-2026

May 01 2026 - Australia
4
Next Week At A Glance – 4-8 May 2026

May 01 2026 - Weekly Reports
5
Weekly Top Ten News Stories – 1 May 2026

May 01 2026 - Weekly Reports

Most Popular

1
FNArena Corporate Results Monitor – 03-04-2026

Apr 03 2026 - Australia
2
ASIC Watch: Reporting Failures Draw $1.1m In Single-Day Fines

Apr 16 2026 - Australia
3
Rudi’s View: Trump’s Circus & Technology’s Brave New World

Apr 09 2026 - Rudi's View
4
AI’s Power Demand Is Rewiring Global Markets

Apr 27 2026 - Commodities
5
In Brief: Reliance, Bannerman & Codan

May 01 2026 - Weekly Reports
6
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps